English

Multiple myeloma is a hematologic malignancy in which abnormal plasma cells may damage the kidneys, bone, and other organ systems.1-4 In the United States, more than 36,000 new diagnoses of multiple myeloma are expected each year, along with more than 12,000 multiple myeloma-associated deaths.5 Assessment of cytogenetic abnormalities and disease staging are important components of

Clinicians must maintain awareness of the latest clinical trials ongoing in the management of multiple myeloma, including those of bispecific antibody therapies targeting BCMA. Selected Clinical Studies of BCMA-Directed Bispecific Antibody Therapies in Multiple Myeloma Treatment Title Link Linvoseltamab (REGN5458) Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed

Multiple myeloma (MM) is cancer of plasma cells. These are differentiated B cells that originate in bone marrow. In the body, plasma cells have an important role in producing antibodies to defend against infections.1 When plasma cells grow in an uncontrolled way, which can occur in multiple myeloma, they suppress the growth of other bone

Antibody therapies augment the naturally occurring antibodies in our immune system that help the immune system recognize infections.1-3 Antibodies have been developed to help identify and attack malignant cells in multiple myeloma and in other cancers. Multiple novel combinations of antibody therapeutics are now available for the management of multiple myeloma. These include: Anti-CD38 antibodies

These resources and organizations can help you navigate therapy and clinical trial opportunities in multiple myeloma. American Cancer Society: ACS Patient Programs and Services Survivorship: During and After Treatment American Society of Clinical Oncology (ASCO): ASCO Resources for Patients & Providers Patient Resources CancerCare: Information, Resources and Support International Myeloma Foundation (IMF): Resources and Support

Krisstina Gowin, DO Hematologist Oncologist and Assistant Professor of Medicine Department of Bone Marrow Transplant and Cellular Therapies University of Arizona Cancer Center Tucson, AZ Craig C. Hofmeister, MD, MPH Hematologist Oncologist Professor in the Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University School of Medicine Atlanta, GA Kenneth Shain, MD,

Having a diagnosis of multiple myeloma can be overwhelming and isolating. With many treatment options available, it is important to discuss the latest therapies with your oncologist and organize a care plan.1 This plan should take into account your goals and preferences, and it is important to understand exactly what to expect from treatment—both in

Online Resources American Cancer Society (ACS). Multiple Myeloma. https://www.cancer.org/cancer/types/multiple-myeloma.html American Society of Hematology (ASH). https://www.hematology.org/education/patients/blood-cancers/myeloma International Myeloma Foundation (IMF). https://www.myeloma.org/ Multiple Myeloma Research Foundation (MMRF). https://themmrf.org/educational-resources/ National Cancer Institute (NCI). https://www.cancer.gov/types/myeloma The Leukemia and Lymphoma Society (LLS). https://www.lls.org/myeloma/myeloma-overview Treatment Recommendations International Myeloma Working Group (IMWG). IMWG Consensus guidelines and recommendations for the management and response

Back to Portal Español Clinical Perspectives: Multiple Myeloma Multiple Myeloma (MM) is a plasma cell cancer producing abnormal antibodies (called M proteins), impacting the kidneys, bones as well as various organs, resulting in infections, kidney impairment or failure, and multiple cell line cytopenias, among other complications. Staying current on treatment guidelines, management approaches, and current/emerging

Many patients have a range of symptoms associated with their disease and have complex needs that require the input of a healthcare team dedicated to the management of multiple myeloma. These can include a hematologist-oncologist who focuses on treatment of blood cancers and a primary care physician.1 In addition, because multiple myeloma can potentially affect